Transthyretin Contributes to Hippocampal Blood-Brain Barrier Recovery Following Intestinal Inflammation, with Reduced Expression in Alzheimer’s Disease
These findings identify transthyretin (TTR) as a contributor of adaptive neurovascular homeostasis during gut-derived neuro inflammation and chronic neuroinflammation, highlighting neurovascular resilience as a potential therapeutic target.
Abstract
Background The blood-brain barrier (BBB) is increasingly recognized as an active immunoregulatory interface that responds dynamically to systemic inflammation. As intestinal inflammation can influence brain homeostasis through the gut-brain axis, the endogenous mechanisms that preserve BBB integrity during gut-derived inflammatory stress remain poorly understood. Methods and Results We combined dextran sulfate sodium-induced colitis, fecal microbiota transplantation, aged mice, APP/PS1 mice, human Alzheimer’s disease (AD) brain tissue, single-cell RNA sequencing, in vivo BBB permeability assays, and gain- and loss-of- function approaches to investigate adaptive neurovascular responses to gut inflammation and their mechanism in maintaining BBB integrity. Intestinal inflammation induced a region- specific adaptive response characterized by increased hippocampal vascular remodeling and partial restoration of BBB integrity following the initial inflammatory insult. Single-cell transcriptomic analysis identified a transthyretin (TTR)-enriched vascular-associated microglial state accompanying these neurovascular changes. Functional studies demonstrated that TTR contributes to maintaining BBB integrity by promoting endothelial homeostasis and limiting endothelial endocytosis, consistent with modulation of FcRn-associated transport pathways. This adaptive neurovascular response was progressively attenuated in aged mice and APP/PS1 mice and was accompanied by reduced vascular TTR expression in human AD brains. Conclusion These findings identify TTR as a contributor of adaptive neurovascular homeostasis during gut-derived neuroinflammation. Impairment of this homeostatic response with aging and AD may contribute to persistent BBB dysfunction and chronic neuroinflammation, highlighting neurovascular resilience as a potential therapeutic target.
S100 calcium-binding protein B (S100B) is conventionally viewed as a marker of astrocytic injury, blood–brain barrier (BBB) disruption, and neurological disorders. Emerging evidence places S100B within the broader brain–gut–liver axis of inflammatory signaling. This review proposes that S100B is a glial-derived integra...
Qi Liu, Ming Yan, Chun-Lei Ji et al.· Frontiers in Immunology· 0 citations
A biphasic inflammatory response is identified, characterized by an initial NFκB-driven peak at 3–6 h, followed by an interferon-mediated phase at 48 h that attenuates by a week, providing insights into establishing therapeutic windows and enhancing neuroinflammatory modulation strategies.
Jane J. Song, Payton J. Martinez, Hannah Lopez et al.· Journal of Neuroinflammation· 0 citations
CD147 exacerbates ischemic brain injury and BBB disruption by suppressing neuronal Wnt/β-catenin signaling through a mechanism involving the AKT/GSK3β node, supporting further evaluation of CD147-directed interventions after stroke.
Yue-Qing Wang, F. Ogunleye, Chong-Lin Xu et al.· Scientific Reports· 0 citations
The blood–brain barrier (BBB) is essential for maintaining central nervous system homeostasis by regulating the exchange of molecules between the brain and circulating blood. Dysfunction of this barrier has been implicated in the progression of several neurodegenerative disorders, including Alzheimer’s disease (A...
Early brain injury (EBI) critically determines post-subarachnoid hemorrhage (SAH) outcome, with worse prognosis in older patients. Aging confers exaggerated inflammation, possibly via gut microbiome (GM) alterations. We investigated whether GM alterations contribute to aging-related worsening of post-SAH EBI and whethe...
T. Fukuda, Masatoshi Takagaki, Hajime Nakamura et al.· Brain Research· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.